Suppression of inducible nitric oxide synthase expression induced by Toll-like receptor agonists by (E)-1-(2-(2-nitrovinyl)phenyl)pyrrolidine

International Immunopharmacology

Volumn 17, Issue 2, 2013, Pages 205-209

  Eom, Sang Hoon ^a   Gu, Gyo Jeong ^a   Suh, Chang Won ^a   Koh, Kwang Oh ^a   Kim, Dae Young ^a   Eom, Yong Bin ^b   Youn, Hyung Sun ^a  

^a Soonchunhyang University   (South Korea)

^b Korea Nazarene University   (South Korea)

Author keywords

(E) 1 (2 (2 nitrovinyl)phenyl)pyrrolidine; Inducible nitric oxide synthase; Inflammation; Nuclear factor B; Toll like receptor

Indexed keywords

1 [2 (2 NITROVINYL)PHENYL]PYRROLIDINE; ANTIINFLAMMATORY AGENT; BETA INTERFERON; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; LIPOPOLYSACCHARIDE; MYELOID DIFFERENTIATION FACTOR 88; NEURONAL NITRIC OXIDE SYNTHASE; POLYINOSINIC POLYCYTIDYLIC ACID; RANTES; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL CELL; ARTICLE; CELL VIABILITY; DRUG CYTOTOXICITY; INNATE IMMUNITY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

(E)-1-(2-(2-NITROVINYL)PHENYL)PYRROLIDINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLAMMATION; NUCLEAR FACTOR-ΚB; TOLL-LIKE RECEPTOR;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE; GENE EXPRESSION REGULATION; LIPOPEPTIDES; LIPOPOLYSACCHARIDES; MICE; MONOCYTES; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; POLY I-C; PYRROLIDINES; STYRENES; TOLL-LIKE RECEPTORS; TRANSCRIPTIONAL ACTIVATION;

EID: 84881511052     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2013.06.006     Document Type: Article

References (19)

1. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001;1: 135-45. (Pubitemid 33741967)
2. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005;17: 1-14.
3. Uematsu S, Akira S. Toll-like receptors and innate immunity. J Mol Med (Berl) 2006;84:712-25. (Pubitemid 44328063)
4. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010;11:373-84.
5. Murakami A, Ohigashi H. Targeting NOX, INOS and COX-2 in inflammatory cells: chemoprevention using food phytochemicals. Int J Cancer 2007;121:2357-63. (Pubitemid 350022403)
6. Moncada S. Nitric oxide: discovery and impact on clinical medicine. J R Soc Med 1999;92:164-9. (Pubitemid 29213859)
7. Vallance P. Nitric oxide: therapeutic opportunities. Fundam Clin Pharmacol 2003;17:1-10. (Pubitemid 36241448)
8. Rabong C, Hametner C, Mereiter K, Kartsev VC, Jordis U. Scope and limitation of T-reaction employing some functionalized C-H-acids and naturally occurring secondary amines. Heterocycles 2008;75:799-838.
9. Youn HS, Lee JY, Fitzgerald KA, Young HA, Akira S, Hwang DH. Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex. J Immunol 2005;175:3339-46. (Pubitemid 41170555)
10. Park SJ, Yun SM, Lee AN, Ahn SI, Lee MY, Youn HS. Costunolide inhibits cyclooxygenase-2 expression induced by Toll-like receptor 3 or 4 agonist. Toxicol Environ Health Sci 2010;1:122-6.
11. Park SJ, Yun SM, Lee AN, Ahn SI, Lee MY, Youn HS. Costunolide inhibits cyclooxygenase-2 expression induced by Toll-like receptor 3 or 4 agonist. Toxicol Environ Health Sci 2009;1:122-6.
12. Park SJ, Youn HS. Isoliquiritigenin suppresses the Toll-interleukin-1 receptor domain-containing adapter inducing interferon-beta (TRIF)-dependent signaling pathway of Toll-like receptors by targeting TBK1. J Agric Food Chem2010;58:4701-5.
13. Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE 2006;2006:re13.
14. Murakami A, Takahashi D, Koshimizu K, Ohigashi H. Synergistic suppression of superoxide and nitric oxide generation from inflammatory cells by combined food factors. Mutat Res 2003;523-524:151-61. (Pubitemid 36293242)
15. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783-801. (Pubitemid 43261452)
16. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 2003;4:491-6. (Pubitemid 36592443)
17. Kawai T, Takeuchi O, Fujita T, Inoue J, Muhlradt PF, Sato S, et al. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharideinducible genes. J Immunol 2001;167:5887-94. (Pubitemid 33062783)
18. Gao JJ, Filla MB, Fultz MJ, Vogel SN, Russell SW, MurphyWJ. Autocrine/paracrine IFN-alphabeta mediates the lipopolysaccharide-induced activation of transcription factor Stat1alpha in mouse macrophages: pivotal role of Stat1alpha in induction of the inducible nitric oxide synthase gene. J Immunol 1998;161: 4803-10. (Pubitemid 28492057)
19. Bjorkbacka H, Fitzgerald KA, Huet F, Li X, Gregory JA, Lee MA, et al. The induction of macrophage gene expression by LPS predominantly utilizes Myd88-independent signaling cascades. Physiol Genomics 2004;19:319-30. (Pubitemid 40039937)